Sunday 18 October 2026
Export AVIR’s income statement to Excel — free account
Atea Pharmaceuticals, Inc.
AVIR Healthcare Biotechnology
In the quarter to June 2026, EPS grew 6.82% and free cash flow grew 85.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
4.32
0.21
−4.64%
Follow AVIR
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 | 6.12 | — | — | — | — |
P/S ratio |
— | — | — | 0.00 | 2.11 | — | — | — | — |
Altman Z-Score |
— | — | — | 2.38 | 9.33 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
— | — | — | 5.65 | 19.38 | — | — | — | — |
P/FCF ratio |
— | — | — | 3.04 | 0.00 | — | — | — | — |
P/Operating CF |
— | — | — | 2.83 | (9.82) | — | — | — | — |
P/B ratio |
— | — | — | 1.65 | 1.04 | — | — | — | — |
Price to Tangible BV |
— | — | — | 1.65 | 1.04 | — | — | — | — |
EV/Sales |
— | — | — | 0.00 | (0.07) | — | — | — | — |
EV/EBITDA |
— | — | — | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
— | — | — | 0.16 | 0.28 | — | — | — | — |
EV/FCF |
— | — | — | 0.16 | 0.28 | — | — | — | — |
Quick Ratio |
— | 19.60 | 8.90 | 2.71 | 13.44 | 35.00 | 17.86 | 24.44 | 7.59 |
Current Ratio |
— | 19.71 | 9.00 | 2.73 | 13.58 | 35.77 | 18.24 | 24.85 | 7.82 |
Net Debt/EBITDA |
— | 3.65 | 1.48 | 77.73 | (5.52) | 4.76 | 3.23 | 2.23 | 1.63 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.11 | 0.43 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.87 | 0.91 | (27.11) | (0.72) | 1.04 | 0.63 | 0.80 | 0.83 |
Capex/Depreciation |
— | (0.71) | (0.12) | (1.37) | (0.14) | 0.37 | 0.00 | 0.00 | 0.00 |
| — | 21.14% | 32.74% | (4.39%) | 19.27% | (17.16%) | (22.74%) | (33.88%) | (44.34%) | |
| — | 0.00% | (127.16%) | (2.47%) | 14.81% | (16.10%) | (21.55%) | (31.78%) | (40.61%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (27.47%) | (71.91%) | (2.00%) | 16.94% | (17.99%) | (24.31%) | (37.87%) | (58.29%) |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 78.18% | 47.59% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 44.50% | 13.03% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 15.33% | 11.28% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | 0.61 | 0.96 | — | — | — | — |
Graham Number |
— | — | — | 0.00 | 16.78 | — | — | — | — |
Earnings Yield |
— | — | — | (1.21%) | 16.33% | — | — | — | — |
Free Cash Flow Yield |
— | — | — | 32.89% | (11.75%) | — | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 2.25 | 4.24 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.79) | (1.27) | 13.74 | (1.05) | (1.45) | (1.02) | (1.61) | (1.62) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.79) | (1.27) | 13.74 | (1.05) | (1.48) | (1.02) | (1.61) | (1.62) |
Cash per Share |
— | 3.44 | 2.15 | 39.64 | 9.23 | 7.77 | 6.93 | 5.40 | 3.70 |
Shareholders Equity per Share |
— | 0.00 | 1.94 | 25.37 | 8.57 | 7.70 | 6.66 | 5.21 | 3.38 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | 1.94 | 25.37 | 8.57 | 7.70 | 6.66 | 5.21 | 3.38 |
Free Cash Flow |
— | (7.92) | (12.83) | 296.71 | (87.01) | (122.92) | (85.39) | (135.50) | (132.03) |
Working Capital |
— | 32.94 | 19.48 | 547.68 | 715.52 | 642.44 | 558.08 | 443.75 | 271.21 |
Capital Expenditures |
— | (0.01) | 0.00 | (0.03) | 0.00 | (1.94) | — | — | — |
Net Current Asset Value |
— | 34.70 | 19.38 | 547.65 | 709.59 | 634.79 | 550.68 | 436.55 | 271.21 |
EV/EBIT |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Price to Operating Income |
— | — | — | 0.00 | 5.35 | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.30 | 0.41 | 0.40 | 1.26 | (3.05) | (11.66) | (13.06) | (9.91) |
Cash ROIC |
— | (22.96%) | (31.14%) | 21.14% | (5.90%) | (9.55%) | (7.54%) | (15.16%) | (22.87%) |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 0.47 | 0.47 | 0.30 | 2.30 | 3.54 | 3.40 | 4.36 | 8.70 |
Average Assets |
— | 0.00 | 11.04 | 442.85 | 818.26 | 719.80 | 630.84 | 529.82 | 389.94 |
Average Common Equity |
— | (42.87) | (42.87) | 249.12 | 628.94 | 675.32 | 597.88 | 497.03 | 357.15 |
Columns are period end dates